Abstract
The nonsteroidal antiestrogen tamoxifen (TAM) is the most commonly used endocrine treatment for all stages of breast cancer in both pre- and postmenopausal women. However, the development of resistance to the drug is common, as most patients treated with TAM eventually experience a recurrence of tumor growth. One of the potential mechanisms of treatment failure is the acquisition by the tumor of the ability to respond to TAM as a stimulatory rather than inhibitory ligand. We (Gottardis and Jordan, Cancer Res 48: 5183-5187, 1988; Wolfet al., J Natl Cancer Inst 85: 806-812, 1993) and others (Osborneet al., Eur J Cancer Clin Oncol 23: 1189-1196, 1987; Osborneet al., J Natl Cancer Inst 83: 1477-1482, 1991) have extensively described the reproducible development of TAM stimulated growth in a laboratory model system using MCF-7 human breast cancer cells grown as solid tumors in athymic mice. In this paper we report on the isolation of an estrogen receptor (ER) from a TAM stimulated tumor (MCF-7/MT2) which contains a point mutation that causes a tyrosine for aspartate substitution at amino acid 351 in the ligand binding domain. The mutant appears to the major form of ER expressed by this tumor. We also report that only wild type ER was detected in three other TAM stimulated MCF-7 tumor variants, suggesting that multiple mechanisms are possible for the development of TAM stimulated growth. The implications of these findings are discussed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Osborne CK, Coronado EB, Robinson JP: Human breast cancer in the athymic nude mouse: cytostatic effects of longterm antiestrogen therapy. Eur J Cancer Clin Oncol 23: 1189–1196, 1987
Gottardis MM, Jordan VC: Development of tamoxifenstimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48: 5183–5187, 1988
Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M: Acquired tamoxifen (TAM) resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83: 1477–1482, 1991
Wolf DM, Langan-Fahey SM, Parker CP, McCague R, Jordan VC: Investigation of the mechanism of tamoxifen stimulated breast tumor growth with non-isomerizable analogs of tamoxifen and its metabolites. J Natl Cancer Inst 85: 806–812, 1993
Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio M: Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 10: 304–310, 1992
Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW: Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 10: 990–994, 1992
Wolf DM, Jordan VC: Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res Treat (this issue)
Vegeto E, Allan GF, Schrader WT, Tsai M-J, McDonnell DP, O'Malley BW: The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 69: 703–713, 1992
Wilding G, Chen M, Gelman EP: Aberrant responsesin vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14: 103–115, 1989
Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Classen C, van Rooij HCJ, Trapman J, Brinkmann AO, Mulder E: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects the steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 173: 534, 1990
Olea N, Sakabe K, Soto AM, Sonnenschein C: The proliferative effect of ‘anti-androgens’ on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology 126: 1457–1463, 1990
Schuurmans ALG, Bolt J, Veldscholte J, Mulder E: Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion. J Steroid Biochem Molec Biol 37: 849–853, 1990
Veldscholte J, Voorhorst-Ogink MM, Bolt-de Vries J, van Rooij HCJ, Trapman J, Mulder E: Unusual specifity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochim Biophys Acta 1052: 187–194, 1990
Jiang S-Y, Jordan VC: Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 84: 580–591, 1992
Jiang S-Y, Langan-Fahey SM, Stella AL, McCague R, Jordan VC: Point mutation of estrogen receptor (ER) in the ligand binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing cDNA's for ER. Mol Endocrinol 6: 2167–2174, 1992
Jiang S-Y, Parker CJ, Jordan VC: A model to describe how a point mutation of the estrogen receptor alters the structure function relationship of antiestrogens. Breast Cancer Res Treat 26: 139–148, 1993
Gottardis MM, Jiang SY, Jeng MH, Jordan VC: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49: 4090–4093, 1989
Wolf DM, Jordan VC: A laboratory model to explain the sustained survival advantage observed in patients taking adjuvant tamoxifen therapy. In: Senn HJ, Goldhirsch A, Gelber RD, Turlmann B (eds) Adjuvant Therapy of Primary Breast Cancer IV. Recent Results in Cancer Research. Springer-Verlag, Berlin, 1993, Vol. 127, pp 22–33
Wolf DM, Arakawa RL, Friedl A, Jordan VC: Estradiol induced regression of the tamoxifen stimulated tumor variant MCF-7 TAM after prolonged exposure to tamoxifenin vivo (in preparation)
Orita M, Suzuki Y, Sekiya T, Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874–879, 1989
Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T: Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86: 2766–2770, 1989
Iwahana H, Yoshimoto K, Itakura M: Detection of point mutations by SSCP of PCR-amplified DNA after endonuclease digestion. BioTechniques 12: 64–65, 1992
Iino Y, Wolf DM, Langan-Fahey SM, Johnson DA, Ricchio M, Thompson ME, Jordan VC: Reversible control of oestradiol-stimulated growth of MCF-7 tumors by tamoxifen in the athymic mouse. Br J Cancer 64: 1019–1024, 1991
Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid-guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156–159, 1987
Green S, Walter P, Kumar V, Krust A, Bornert J-M, Argos P, Chambon P: Human oestrogen receptor cDNA; sequence, expression and homology to v-erbA. Nature 320: 134–139, 1986
Tora L, Mullick A, Metzger D, Ponglikitmongkol M, Park I, Chambon P: The cloned human estrogen receptor contains a mutation which alters its hormone binding properties. EMBO J 8: 1981–1986, 1989
Chung CT, Miller RH: A rapid and convenient method for the preparation and storage of competent bacterial cells. Nucleic Acids Res 16: 3580, 1988
Fuqua SAW, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP, O'Malley BW, Greene GL, McGuire WL: Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 52: 483–486, 1992
Cole MP, Jones CJA, Todd IDH: A new antioestrogenic agent in late breast cancer. Br J Cancer 25: 270–275, 1971
Tanaka M, Abe K, Ohnami S, Adachi I, Yamaguchi K, Miyakawa S: Tamoxifen in advanced breast cancer: response rate, effect on pituitary hormone reserve and binding affinity to estrogen receptor. Jpn J Clin Oncol 8: 141–148, 1978
Smith IE, Harris AL, Morgan M, Ford HT, Gazet J, Harmes CL, White H, Parsons CA, Villardo A, Walsh G, McKinna JA: Tamoxifenversus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J 283: 1432–1434, 1981
Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Greagan ET, Hahn RG, Rubin J, Frytak S: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304: 16–21, 1981
Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339: 1–15, 71-85, 1992
Legault-Poisson S, Jolivet J, Poisson R, Beretta-Piccoli M, Band PR: Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat Rep 63: 1839–1841, 1979
Canney PA, Griffiths T, Latief TN, Priestman TJ: Clinical significance of tamoxifen withdrawal response. Lancet i: 36, 1987
Belani CP, Pearl P, Whitley NO, Aisner J: Tamoxifen withdrawal response. Report of a case. Archives of Internal Medicine 149: 449–450, 1989
Howell A, Dodwell DJ, Anderson H, Redford J: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 3: 611–617, 1992
Walker KJ, Price-Thomas JM, Candlish W, Nicholson RI: Influence of the antioestrogen tamoxifen on normal breast tissue. Br J Cancer 64: 764–768, 1991
Fritsch M, Wolf DM: Symptomatic side effects of tamoxifen therapy. In: Jordan VC (ed) Long-Term Tamoxifen Treatment for Breast Cancer. University of Wisconsin Press, Madison (in press)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wolf, D.M., Jordan, V.C. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Tr 31, 129–138 (1994). https://doi.org/10.1007/BF00689683
Issue Date:
DOI: https://doi.org/10.1007/BF00689683